A recent study reveals that patients who come off popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle plans.
Research printed in a major health publication demonstrates that while obese people frequently drop a large proportion of their body weight while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users using these drugs must be informed of the risk of rapid rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
This pace of recovery suggests a return to original weight in about 18 months.
Comparing Treatments
The study, which reviewed dozens of studies involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
Scientists emphasize that people who shed pounds through diet and exercise generally have a less rapid creep back—around 0.1 kg a month—after stopping.
Explaining the Fast Regain
Doctors suggest the mode of action of the drugs explains the amplified weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating a significant risk."
A Chronic Disease?
The NHS recommend the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, given the high risk of relapse, the treatment might need to be long-term.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the persistent nature of excess weight," similar to managing conditions like hypertension.
User Experiences
Users who have stopped the jabs report a sudden return of cravings.
"I experienced something activating and you're instantly starving," recalled a patient.
This difficulty is compounded if users have not developed sustainable lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates show that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is greater among females than men.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and lasting health benefits hinges on integrated behavioural management.
